Estuary Biotherapeutics Raises $103 Million for ADPKD
The startup plans to move its lead gene therapy into clinical trials by 2027 to address a common cause of kidney failure.
Updated on Oct. 16, 2026 in Biotech
Live Poll
Should the development of expensive gene therapies be the primary focus of modern medical research?
Estuary Biotherapeutics has emerged from stealth mode with $103 million in total funding to develop gene therapies for autosomal dominant polycystic kidney disease (ADPKD). The company is currently in the research stage, working to progress its candidates toward clinical trials.
Why it matters
The company aims to address a condition where current treatment options are limited to a single FDA-approved drug. By targeting the genetic root of the disease, this approach seeks to halt or reverse cyst growth, which is the primary cause of kidney failure in affected patients.
Estuary Biotherapeutics is developing EST-201 and EST-101 to treat mutations in the PKD1 and PKD2 genes, which account for 90% of ADPKD cases. These candidates use an adeno-associated virus (AAV) — a modified, harmless virus used as a delivery vehicle — to restore protein levels across the nephron.
The players
Estuary Biotherapeutics
A biotechnology startup developing gene therapies for polycystic kidney disease using AAV-based delivery platforms.
RA Capital Management
An investment firm specializing in healthcare and life sciences that led the company's Series A funding round.
Stefan Somlo
A Yale School of Medicine professor whose research into kidney disease genetics underpins the company's therapeutic approach.
Michael Caplan
A Yale School of Medicine professor whose research into kidney disease genetics underpins the company's therapeutic approach.
Otsuka Pharmaceutical
A global pharmaceutical company that markets tolvaptan, currently the only FDA-approved drug for treating ADPKD.
The details
The therapies work by delivering corrective genetic payloads directly to kidney epithelial cells — the cells that line the inside and outside of the kidney's structural units. By transducing these cells, the treatment aims to modulate protein levels across the nephron, the functional unit of the kidney, to prevent the formation of fluid-filled cysts. This mechanism represents a shift from symptom management to addressing the underlying genetic pathology.
Timeline
2027: Estuary expects to move EST-201 into clinical trials.
2028: Estuary expects to enter EST-101 into clinical trials.
The Tech Race
Estuary Biotherapeutics is entering a space where treatment has long been dominated by small-molecule drugs like tolvaptan. This effort signals a move toward genetic interventions in kidney disease, following broader industry consolidation like Novartis's $1.7 billion move in the space.
Patients with ADPKD will not see these therapies in clinics for several years, as they are currently in the research stage. The development primarily affects the pipeline for nephrology treatments and represents a shift in potential future care for those with PKD1 or PKD2 mutations.
The takeaway
The firm is moving to address the genetic root of ADPKD rather than just slowing cyst expansion. Interested parties should track the publication of preclinical efficacy benchmarks for EST-201 and EST-101 as the company approaches its 2027 clinical trial target.
What happens next
Estuary Biotherapeutics plans to initiate clinical trials for EST-201 in 2027, followed by trials for EST-101 in 2028.
Further reading
For more on the latest research in genetic medicine, visit our Biotech section.
Live Poll
Should the development of expensive gene therapies be the primary focus of modern medical research?
